InsidersTradesSigma
Total declarations
Company
▲ Purchases (44 ops.)
▼ Sales (0 ops.)
Browse the full record of transactions filed by Cambrian BioPharma Inc, Chief Executive Officer. Officer active across 1 companies, notably Sensei Biotherapeutics, Inc.. Aggregated, 45 filings have been recorded. Total volume traded: €2.3m. The latest transaction was filed on 10 June 2022 — Attribution. Regulator: SEC (Form 4). The full history is openly available.
Declarations45 total
04,466 shares0
Restricted Stock Unit Grant
SEC:0001567619-22-012842:0·
€3,4581,203 shares@ €2.87440.013% mcap0.1% of flow
Common Stock
SEC:0001567619-22-012646:0·
Ideal exit: 27 Nov 2022 (T+270)
€114,1629,500 shares@ €12.01710.42% mcap4.9% of flow
Common Stock
SEC:0001567619-22-008800:0·
Ideal exit: 18 Dec 2021 (T+270)
€12,327752 shares@ €16.39280.045% mcap0.5% of flow
Common Stock
SEC:0001567619-22-008798:0·
Ideal exit: 15 Nov 2021 (T+270)
€3,4581,203 shares@ €2.87440.013% mcap0.1% of flow
Common Stock
SEC:0001567619-22-006007:0·
Ideal exit: 27 Nov 2022 (T+270)
€13542 shares@ €3.21970.0005% mcap0.0% of flow
Common Stock
SEC:0001567619-22-005913:0·
Ideal exit: 25 Nov 2022 (T+270)
€8,1542,500 shares@ €3.26160.030% mcap0.4% of flow
Common Stock
SEC:0001567619-22-005791:0·
Ideal exit: 22 Nov 2022 (T+270)
€8,3852,500 shares@ €3.35420.031% mcap0.4% of flow
Common Stock
SEC:0001567619-22-005518:0·
Ideal exit: 20 Nov 2022 (T+270)
€18,1424,949 shares@ €3.66580.066% mcap0.8% of flow
Common Stock
SEC:0001567619-22-005190:0·
Ideal exit: 14 Nov 2022 (T+270)
€36,77910,000 shares@ €3.67790.13% mcap1.6% of flow
Common Stock
SEC:0001567619-22-004779:0·
Ideal exit: 11 Nov 2022 (T+270)
€20,0505,000 shares@ €4.010.073% mcap0.9% of flow
Common Stock
SEC:0001567619-22-004543:0·
Ideal exit: 7 Nov 2022 (T+270)
€72,01417,500 shares@ €4.11510.26% mcap3.1% of flow
Common Stock
SEC:0001567619-22-002937:0·
Ideal exit: 31 Oct 2022 (T+270)
€72,01417,500 shares@ €4.11510.26% mcap6.9% of flow
Common Stock
SEC:0001567619-22-002937·
Ideal exit: 31 Oct 2022 (T+270)
€23,3836,100 shares@ €3.83330.085% mcap2.2% of flow
Common Stock
SEC:0001567619-22-002036·
Ideal exit: 24 Oct 2022 (T+270)
€23,3836,100 shares@ €3.83330.085% mcap1.0% of flow
Common Stock
SEC:0001567619-22-002036:0·
Ideal exit: 24 Oct 2022 (T+270)
€86,26420,100 shares@ €4.29170.31% mcap8.3% of flow
Common Stock
SEC:0001567619-22-001801·
Ideal exit: 22 Oct 2022 (T+270)
€86,26420,100 shares@ €4.29170.31% mcap3.7% of flow
Common Stock
SEC:0001567619-22-001801:0·
Ideal exit: 22 Oct 2022 (T+270)
€107,86224,703 shares@ €4.36640.39% mcap4.7% of flow
Common Stock
SEC:0001567619-22-001632:0·
Ideal exit: 18 Oct 2022 (T+270)
€107,86224,703 shares@ €4.36640.39% mcap10.3% of flow
Common Stock
SEC:0001567619-22-001632·
Ideal exit: 18 Oct 2022 (T+270)
€44,93810,244 shares@ €4.38670.16% mcap4.3% of flow
Common Stock
SEC:0001567619-22-001462·
Ideal exit: 16 Oct 2022 (T+270)
€44,93810,244 shares@ €4.38670.16% mcap1.9% of flow
Common Stock
SEC:0001567619-22-001462:0·
Ideal exit: 16 Oct 2022 (T+270)
€44,52010,000 shares@ €4.4520.16% mcap4.3% of flow
Common Stock
SEC:0001567619-22-001340·
Ideal exit: 15 Oct 2022 (T+270)
€44,52010,000 shares@ €4.4520.16% mcap1.9% of flow
Common Stock
SEC:0001567619-22-001340:0·
Ideal exit: 15 Oct 2022 (T+270)
€89,46219,953 shares@ €4.48360.33% mcap8.6% of flow
Common Stock
SEC:0001567619-22-001228·
Ideal exit: 10 Oct 2022 (T+270)
€89,46219,953 shares@ €4.48360.33% mcap3.9% of flow
Common Stock
SEC:0001567619-22-001228:0·
Ideal exit: 10 Oct 2022 (T+270)
25 of 45 declarations
About Cambrian BioPharma Inc
James Peyer is the Chief Executive Officer and co-founder of Cambrian BioPharma Inc., a biotechnology company focused on longevity science and therapeutics aimed at extending healthspan. In this role, he leads the company’s overall strategy, scientific direction, and operating model, including its distributed development approach, which is designed to advance multiple therapeutic programs in parallel. Cambrian’s official materials also identify him as a Board Director of the company. His professional path is closely tied to building Cambrian and advancing academic discoveries toward clinical development. Cambrian describes him as the founder of the company and notes that its mission is to bridge the gap between scientific discovery and drug development by creating institutional-grade development capabilities. He has also been central to shaping the company’s portfolio strategy and to announcing programs connected to Sensei Biotherapeutics, Inc., which is referenced as one of the companies emerging from the Cambrian ecosystem. Based on the sources reviewed, Peyer is associated with several important strategic decisions, including assembling an experienced leadership team, establishing a portfolio of companies and assets under the DisCo model, and strengthening clinical development capabilities. Cambrian has emphasized his role in building an organization that can support multiple programs rather than a single asset. His expertise therefore appears to sit at the intersection of biotech strategy, financing, clinical development organization, and operational execution. Because the public sources reviewed do not provide a complete historical biography, it would be inappropriate to invent earlier roles or specific prior employers. What can be verified is that Peyer is a founder-led biotechnology executive with a strong focus on longevity-oriented company building, portfolio creation, and the translation of promising science into development-stage programs. In SEO terms, he can be characterized as a biotech CEO and founder with notable experience in strategic platform building, scientific program selection, and corporate development in the U.S. life sciences market.
